Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Critical Care Medicine

• Publication date

  1998-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00003246-199812000-00021PMID 9875905
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vivo inhibition of plasma protein leakage andSalmonella enteritidis—induced mortality in the rat by a specific paf-acether antagonist: BN 52021

  2005cited by this paper
• The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.

  1997cited by this paper
• p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.

  1997cited by this paper
• Influence of alterations in foregoing life-sustaining treatment practices on a clinical sepsis trial. The HA-1A Sepsis Study Group.

  1997cited by this paper
• Influence of alterations in forgoing life-sustaining treatment practices on a clinical sepsis trial

  1997cited by this paper
• From the bench to the bedside: the future of sepsis research. Executive summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop.

  1997cited by this paper
• p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock: A Randomized Controlled Multicenter Trial

  1997cited by this paper
• Lipid mediator networks in cell signaling: update and impact of cytokines 1

  1996cited by this paper
• INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

  1996cited by this paper
• Lessons learned from clinical trials of sepsis

  1995cited by this paper
• Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial

  1995cited by this paper
• Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993.

  1995cited by this paper
• Platelet-activating factor antagonists

  1995cited by this paper
• Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

  1995cited by this paper
• Round table conference on clinical trials for the treatment of sepsis.

  1995cited by this paper
• Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. The Ginkgolide Study Group in multiple sclerosis.

  1995cited by this paper
• Another negative clinical trial of a new agent for the treatment of sepsis: rethinking the process of developing adjuvant treatments for serious infections.

  1995cited by this paper
• Evaluation of definitions of sepsis.

  1994cited by this paper
• Nosocomial Bloodstream Infection in Critically Ill Adults: Excess Length of Stay, Extra Costs, and Attributable Mortality

  1994cited by this paper
• Plasma degradation of platelet‐activating factor in severely ill patients with clinical sepsis

  1994cited by this paper
• BN 52021: A Platelet Activating Factor Antagonist for Preventing Post-Transplant Renal Failure: A Double-Blind, Randomized Study

  1994cited by this paper
• Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

  1994cited by this paper
• Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

  1994cited by this paper
• Antiendotoxin Antibodies: A Dead End?

  1994cited by this paper
• Platelet‐activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double‐blind, placebo‐controlled, multicenter clinical trial

  1994cited by this paper
• Effects of the platelet-activating factor receptor antagonist BN 52021 on hematologic variables and blood loss during and after cardiopulmonary bypass.

  1994cited by this paper
• Sepsis therapy trials. Continued disappointment or reason for hope?

  1994cited by this paper
• A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study.

  1993cited by this paper
• A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study

  1993cited by this paper
• Evaluation of definitions for sepsis.

  1992cited by this paper
• Endotoxin and Staphylococcus aureus enterotoxin A induce different patterns of cytokines.

  1992cited by this paper
• Differing roles for platelet-activating factor during inflammation of the lung and subarachnoid space. The special case of Streptococcus pneumoniae.

  1992cited by this paper
• Anti-endotoxin monoclonal antibodies--a second look.

  1992cited by this paper
• PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

  1991cited by this paper
• Platelet Activating Factor (PAF)

  1991cited by this paper
• Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist.

  1990cited by this paper
• Endotoxin releases platelet-activating factor from human monocytes in vitro.

  1990cited by this paper
• Relationships between tumour necrosis factor, eicosanoids and platelet‐activating factor as mediators of endotoxin‐induced shock in mice

  1990cited by this paper
• Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group.

  1989cited by this paper
• Sepsis syndrome: a valid clinical entity

  1989cited by this paper
• Occupancy of platelet receptors for platelet-activating factor in patients with septicemia.

  1989cited by this paper
• PAF/cytokine auto-generated feedback networks in microvascular immune injury: consequences in shock, ischemia and graft rejection.

  1989cited by this paper
• An expanded definition of the adult respiratory distress syndrome.

  1988cited by this paper
• Intravascular release of platelet activating factor in children with sepsis.

  1987cited by this paper
• Protective effect of a PAF-acether antagonist, BN 52021, in trichothecene toxicosis.

  1987cited by this paper
• Platelet-activating factor antagonists.

  1987cited by this paper
• Prostaglandins, leukotrienes, and platelet-activating factor in shock.

  1987cited by this paper
• Inhibition of rat endotoxin-induced lethality by BN 52021 and BN 52063, compounds with PAF-acether antagonistic effect and protease-inhibitory activity.

  1987cited by this paper
• Interference of BN 52021, a PAF-acether antagonist, with endotoxin-induced hypotension in the guinea-pig.

  1986cited by this paper

• Antagonizing epigenetically controlled PAF/PAF-R pathway improves liver function during experimental cirrhosis.

  2025cites this paper
• The End of “One Size Fits All” Sepsis Therapies: Toward an Individualized Approach

  2022cites this paper
• Chasing the Ghost: Hyperinflammation Does Not Cause Sepsis

  2022cites this paper
• Statin Therapy May Be Associated with Reduced Mortality Risk of Sepsis Patients: A Retrospective Study from the MIMIC-IV Database

  2021cites this paper
• Activation of Neutrophil Granulocytes by Platelet-Activating Factor Is Impaired During Experimental Sepsis

  2021cites this paper
• Targeting of G-protein coupled receptors in sepsis.

  2020cites this paper
• Current problems in burn immunology.

  2020cites this paper
• Which Multicenter Randomized Controlled Trials in Critical Care Medicine Have Shown Reduced Mortality? A Systematic Review.

  2019cites this paper
• Platelet-activating factor (PAF) mediates NLRP3-NEK7 inflammasome induction independently of PAFR

  2019cites this paper
• Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives

  2019cites this paper
• The systemic inflammatory response syndrome

  2018cites this paper
• Chapter 22 – Meta-analysis of Clinical Trials

  2018cites this paper
• The Systemic Inflammatory Response Syndrome ( SIRS ) , Sepsis , and Septic Shock

  2017cites this paper
• Anti-inflammatory Effects of Oct4/Sox2-overexpressing Human Adipose Tissue-derived Mesenchymal Stem Cells.

  2017cites this paper
• Diagnose der Infektion und Stellenwert von Biomarkern

  2016cites this paper
• NLF20: an antimicrobial peptide with therapeutic potential against invasive Pseudomonas aeruginosa infection.

  2016cites this paper
• Biosynthesis of oxidized lipid mediators via lipoprotein-associated phospholipase A2 hydrolysis of extracellular cardiolipin induces endothelial toxicity.

  2016cites this paper
• Sepsis: in search of cure

  2016cites this paper
• Non-cultured dermal-derived mesenchymal cells attenuate sepsis induced by cecal ligation and puncture in mice

  2015cites this paper
• Current Perspectives on the Beneficial Role of Ginkgo biloba in Neurological and Cerebrovascular Disorders

  2015cites this paper
• Platelets in the immune response: Revisiting platelet-activating factor in anaphylaxis.

  2015cites this paper
• The regulatory role of immunosuppressants on immune abnormalities in acute pancreatitis.

  2014cites this paper
• Two Decades of Mortality Trends Among Patients With Severe Sepsis: A Comparative Meta-Analysis*

  2014cites this paper
• tumor necrosis factor (TNF)-α and interleukin (IL)‐1 levels, which are the initiating factors for the inflammatory cytokine cascade (9‐12), inflammatory cell infiltration, local blood circu- lation dysfunction and autoimmune self-destruction (13-16). Pancreatitis and autoimmune disorders use NF-κB a

  2014cites this paper
• Strategies to improve drug development for sepsis

  2014cites this paper
• How to Use a Subgroup Analysis

  2014cites this paper
• How to use a subgroup analysis: users' guide to the medical literature.

  2014cites this paper
• Septic shock: new pharmacotherapy options or better trial design?

  2013cites this paper
• Protective Effects of Huang-Lian-Jie-Du-Tang against Polymicrobial Sepsis Induced by Cecal Ligation and Puncture in Rats

  2013cites this paper
• The TFPI-2 Derived Peptide EDC34 Improves Outcome of Gram-Negative Sepsis

  2013cites this paper
• Animal models of sepsis

  2013cites this paper
• SECTION A: Septicemia,Toxin-andInflammation-MediatedSyndromes PART II Clinical Syndromes and Cardinal Features of Infectious Diseases: Approach to Diagnosis and Initial Management

  2012cites this paper
• Advances in Sepsis Therapy

  2012cites this paper
• Meta-analysis of Clinical Trials

  2012cites this paper
• Innovative Therapies for Sepsis

  2012cites this paper
• Translational research in sepsis - an ultimate challenge?

  2011cites this paper
• Immune-modulating interventions in critically ill septic patients: pharmacological options

  2011cites this paper
• Harvesting, identification and barrier function of human lung microvascular endothelial cells.

  2010cites this paper
• Factors Influencing the Efficacy of Mediator‐Specific Anti‐Inflammatory, Glucocorticoid, and Anticoagulant Therapies for Sepsis

  2010cites this paper
• Critical care trial design and interpretation: A primer

  2010cites this paper
• Are the concepts of SIRS and MODS useful in sepsis

  2010cites this paper
• The Agonists of Formyl Peptide Receptors Prevent Development of Severe Sepsis after Microbial Infection

  2010cites this paper
• Noncolligative properties of intravenous fluids.

  2010cites this paper
• Noncolligative properties of intr avenous fluids

  2010cites this paper
• New insights into acute lung injury.

  2010cites this paper
• The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses.

  2010cites this paper
• Microbial Infection Prevent Development of Severe Sepsis after The Agonists of Formyl Peptide Receptors

  2010cites this paper
• Randomized controlled trialが異なる結果を出すのはなぜか

  2009cites this paper
• Has Mortality from Sepsis Improved and What to Expect from New Treatment Modalities: Review of Current Insights

  2009cites this paper
• Improving clinical trials in the critically ill: Unique challenge—Sepsis

  2009cites this paper
• Multicenter, randomized, controlled trials evaluating mortality in intensive care: Doomed to fail?

  2008cites this paper
• New therapies for sepsis.

  2008cites this paper
• Multiple Organ Dysfunction Syndrome

  2008cites this paper
• Death in a Lonely Place: Pathophysiology of the Dying Patient

  2008cites this paper
• Infectious Diseases in the Pediatric Intensive Care Unit

  2008cites this paper
• Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study.

  2007cites this paper
• Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin.

  2007cites this paper
• Immunomodulation by n-3- versus n-6-rich lipid emulsions in murine acute lung injury—Role of platelet-activating factor receptor

  2007cites this paper
• Using Secondary Data in Statistical Analysis

  2007cites this paper
• Drotrecogin alfa (activated) in the treatment of severe sepsis.

  2007cites this paper
• Clinical trials in spontaneous disease in dogs: a new paradigm for investigations of sepsis

  2007cites this paper
• Leptin: at the crossroads of energy balance and systemic inflammation.

  2007cites this paper
• Mechanism of F-actin crosslinking by filamin A and the anti-inflammatory functions of plasma gelsolin in bodily fluids

  2007cites this paper
• Neutrophils in development of multiple organ failure in sepsis.

  2006cites this paper
• Drotrecogin alfa (activated) in the treatment of severe sepsis

  2006cites this paper
• International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH

  2006cites this paper
• Effect of Intraperitoneal Application of an Endotoxin Inhibitor on Survival Time in a Laparoscopic Model of Peritonitis in Rats

  2005cites this paper
• Estimating sample size in critical care clinical trials.

  2005cites this paper
• Regulating inflammation through the anti-inflammatory enzyme platelet-activating factor-acetylhydrolase.

  2005cites this paper
• Sepsis and coagulation.

  2005cites this paper
• Therapeutic intervention and targets for sepsis.

  2005cites this paper
• Interférences avec la cascade immuno-inflammatoire

  2005cites this paper
• Mechanisms of platelet-activating factor (PAF)-mediated responses in the lung.

  2005cites this paper
• Ginkgolide B stimulates signaling events in neutrophils and primes defense activities.

  2005cites this paper
• Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis

  2005influential citation
• Sources of variability on the estimate of treatment effect in the PROWESS trial: Implications for the design and conduct of future studies in severe sepsis*

  2004cites this paper
• Mediator modulation therapy of severe sepsis and septic shock: does it work?

  2004cites this paper
• Highly Purified Vitamin B2 Presents a Promising Therapeutic Strategy for Sepsis and Septic Shock

  2004cites this paper
• The dark side of C5a in sepsis

  2004cites this paper
• A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker

  2004cites this paper
• Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*

  2004cites this paper
• Evidence-based medicine in the ICU: important advances and limitations.

  2004cites this paper
• Efficacy and Safety of the Platelet-Activating Factor Receptor Antagonist BN 52021 (Ginkgolide B) in Patients with Severe Sepsis

  2004cites this paper
• Should we continue to target the platelet-activating factor pathway in septic patients?

  2004cites this paper
• Endpoints in sepsis trials: More than just 28-day mortality?

  2004cites this paper
• The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*

  2003cites this paper
• Platelet activating factor inhibition in sepsis: the end?

  2003cites this paper
• Inflammation and coagulation: implications for the septic patient.

  2003cites this paper
• Recent developments in the treatment of sepsis

  2003cites this paper
• Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.

  2003cites this paper
• Pharmacologic treatment of acute renal failure in sepsis

  2003cites this paper
• Entwicklungen in der Sepsis-Therapie und aktuelle Behandlungskonzepte

  2003cites this paper
• Prevention and treatment of progressive multiple organ disfunction in acute pancreatitis

  2003cites this paper
• Pathogenese und Therapie der Sepsis

  2003cites this paper
• Quelles perspectives thérapeutiques dans le syndrome septique

  2003cites this paper
• Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome.

  2003cites this paper
• Cytokine therapeutics for the treatment of sepsis: why has nothing worked?

  2003cites this paper
• PLATELET‐ACTIVATING FACTOR ACETYLHYDROLASE INHIBITS ALVEOLAR MACROPHAGE ACTIVATION IN VIVO

  2003cites this paper
• [Which therapeutic prospects in the septic syndrome?].

  2003cites this paper
• Anti-inflammatory strategies for the treatment of sepsis

  2003cites this paper